🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,435 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12428403

N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonis

Takeda Pharmaceutical Company Limited · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421188

Heterocyclic compound and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12419890

Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415782

Heterocyclic compound and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415866

Monoclonal antibody inhibitor of Factor XIIa

Takeda Pharmaceutical Company Limited · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12409210

CNS delivery of therapeutic agents

Takeda Pharmaceutical Company Limited · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12403154

Administration of sting agonist and checkpoint inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12404237

Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl

Takeda Pharmaceutical Company Limited · Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391765

Methods and materials for assessing response to plasmablast- and plasma cell-depleting the

Takeda Pharmaceutical Company Limited · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391739

Method for producing gamma delta T cells

Takeda Pharmaceutical Company Limited · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391760

Method of treating primary sclerosing cholangitis

Takeda Pharmaceutical Company Limited · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12384770

Heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12384854

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Takeda Pharmaceutical Company Limited · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12383587

AAV triple-plasmid system

Takeda Pharmaceutical Company Limited · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12377078

Viral inhibitors, the synthesis thereof, and intermediates thereto

Takeda Pharmaceutical Company Limited · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12378256

Heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12371506

Subcutaneous administration of anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12370192

Azole-fused pyridazin-3(2H)-one derivatives

Takeda Pharmaceutical Company Limited · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12364791

Conformal coating of biological surfaces

Takeda Pharmaceutical Company Limited · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12365723

Human plasma-derived IGG preparation enriched in anti-parvo B19 natural IGGS

Takeda Pharmaceutical Company Limited · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12358879

Heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12359178

Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase

Takeda Pharmaceutical Company Limited · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12351824

Method for producing natural killer cells from pluripotent stem cells

Takeda Pharmaceutical Company Limited · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338249

Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3

Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted